Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$2.67 USD
-0.01 (-0.37%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $2.68 +0.01 (0.37%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OBIO 2.67 -0.01(-0.37%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates
Other News for OBIO
Orchestra BioMed secures over $111M in proceeds, committed capital
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following ...
12 Health Care Stocks Moving In Friday's Intraday Session
Orchestra BioMed (OBIO) Sets Public Offering at $2.75 Per Share
Orchestra BioMed announces pricing of $40 million public offering